Search
Aceclofenac
go.drugbank.com/drugs/DB06736ApprovedIt is a more commonly prescribed drug in Europe. … It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670].
Synonyms: 2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acid, 2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acidMixtures: ZERODOL PCD68-ET3-LV
go.drugbank.com/drugs/DB32864InvestigationalCD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalx 10^9/L were administered lusutrombopag orally [L4166]. … TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingZiprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigational[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525] … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsProducts: GEODON® CAPSULAS 80 MG, ICIN KURU TOZ ICEREN FLAKON 20MG/ML FLAKON, 1 ADETAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274] … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: ANAGRELID AL 0.5MG HKP, ANAGRELID RATIO 1 MGTalarozole
go.drugbank.com/drugs/DB13083InvestigationalTalarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 Enzyme InhibitorsEtrolizumab
go.drugbank.com/drugs/DB12189InvestigationalInflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as
RLYB212
go.drugbank.com/drugs/DB17727InvestigationalRLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Synonyms: Recombinant human IgG monoclonal HPA-1a antibodyTrichlormethiazide
go.drugbank.com/drugs/DB01021ApprovedVet approvedA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Categories: Heterocyclic Compounds, 2-RingElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalMoreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors